Antidepressant Drugs Industry

Increase in prevalence of depression, geriatric population, emergence of novel techniques for the development of drug with fewer side-effects drive the market.

PORTLAND, OR, UNITED STATES, November 26, 2021 /EINPresswire.com/ -- Depression affects a person's thoughts, behavior, feelings and sense of well-being and is caused due to biological, genetics, environment, and psychological factors. The symptoms usually include low mood and aversion to physical activity. Depression is more common in women than men. Depression drugs works by fixing chemical imbalance such as lack of serotonin in the brain. Antidepressants helps in the treatment of depression by maintaining balance of various hormones and chemicals in the brain. Although effective treatments are available, many individuals with depression do not have access to treatment or do not take treatment, mainly due to lack of knowledge and social stigma.

The antidepressant drugs market accounted for $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023. North America is the highest contributor in the antidepressant drugs market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/2593

The rise in geriatric population, increase in prevalence of depression, and emergence of novel techniques for the development of drugs with fewer side-effects majorly drive the market growth. Furthermore, increase in awareness regarding the disease state and rise in number of people suffering from stress can fuel the growth of the antidepressant drugs market. However, poor efficacy and safety profiles of the drug, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

Among the depressive disorder, major depressive disorder is the dominant segment as majority of the people are usually diagnosed with this disorder due to increase in stress levels. However, obsessive compulsive disorder is the fastest growing segment due to increase in the number of drugs for this disorder.
Among the product, selective serotonin reuptake inhibitors dominate the market owing to the large number of prescription of this drugs and large number of clinical trials for these drugs.

In 2016, North America was the dominant revenue contributor, owing to the high prevalence rate of depression, presence of high disposable income, and increase in number of prescriptions for antidepressants. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to presence of populace countries such as India and China leading to large number of people suffering from depression and rise in healthcare expenditure.

The Major Key Players Are:

• Alkermes Plc
• Allergan Plc
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• H. Lundbeck
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.

The Other Prominent Players Are:

• Opko Health
• Intra-Cellular Therapies
• Janssen Pharmaceuticals
• Lupin
• Abbott Laboratories
• Novartis
• Forest Laboratories
• AstraZeneca

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2593

Key Findings of the Antidepressant Drugs Market:

• Obsessive compulsive disorder is projected to grow at the highest rate during the analysis period.
• North America dominated global antidepressant drugs market in 2016, and is projected to continue its dominance in future.
• China is expected to grow highest in Asia-Pacific during the forecast period.
• Major depressive disorder is the largest contributor among the depressive disorder segments in 2016.
• Selective serotonin reuptake inhibitors segment generated the highest revenue, and is expected to continue its dominance in future.

Trending Reports in Healthcare Industry

South Korea ECG Market Analysis, Industry Forecast, 2030

Cholera Vaccine Market Analysis, Industry Forecast, 2030

Osseointegration Implants Market Analysis, Industry Forecast, 2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.